Due to the abnormally high expression of SLC7A11 in HCC, which is negatively correlated with antitumor immunity and clinical prognosis, inhibiting SLC7A11 and promoting ferroptosis may be a promising strategy for HCC treatment. Here, SLC7A11 is linked to hepatocellular carcinoma.